Delisting riskPopularity #4,337
GRI · NASDAQ · Biotechnology

GRI Bio (GRI)

Develops NKT-cell therapies for pulmonary fibrosis and autoimmune disease.

$2.08
vs last close+0.03 (+1.46%)